Document is current
Any future updates will be listed below
-
Authors
Talebi, Ali
de Laat, Vincent
Spotbeen, Xander
Dehairs, Jonas
Rambow, Florian
Rogiers, Aljosja
Vanderhoydonc, Frank
Rizotto, Lara
Planque, Mélanie
Doglioni, Ginevra
Motamedi, Sahar
Nittner, David
Roskams, Tania
Agostinis, Patrizia
Bechter, Oliver
Boecxstaens, Veerle
Garmyn, Marjan
O’Farrell, Marie
Wagman, Alan
Kemble, George
Leucci, Eleonora
Fendt, Sarah-Maria
Marine, Jean-Christophe
Swinnen, Johannes V. https://orcid.org/0000-0002-7720-5077
-
Funding
Funding for this research was provided by:
Research Foundation Flanders
Kom op tegen Kanker (ZKD5294/10238146)
Stichting Tegen Kanker (2016-054)
KU Leuven
EU Interreg (EMR23)
European Research Council
Fonds Baillet Latour
- License Information
-
More Information
Article History
Received: 21 December 2022
Accepted: 5 April 2023
First Online: 19 April 2023
Declarations
:
: Written informed consent was obtained from patients and all procedures involving human samples were approved by the UZ Leuven/KU Leuven Medical Ethical Committee (S54185) and carried out in accordance with the principles of the Declaration of Helsinki. The experiments were approved by the KU Leuven animal ethical committee under ECD P038-2015 and performed in accordance with the internal, national and European guidelines of Animal Care and Use.
: Not applicable
: Marie O’Farrell and George Kemble are employees of Sagimet Biosciences (formerly 3-V Biosciences). Allan Wagman is a former employee of 3-V Biosciences. SMF has received funding from Bayer, Merck and BlackBelt Therapeutics and has consulted for Funds + . The other authors declare no competing financial interests.
